4DMedical Limited (ASX:4DX) Unveils Groundbreaking CT:VQ Technology

CT:VQ Presentation Highlights

4DMedical Limited (ASX: 4DX) has showcased its innovative ventilation and perfusion technology, CT:VQ, at the Radiological Society of North America Annual Meeting (RSNA 2024). The presentation highlighted the significant market opportunity presented by CT:VQ as a $1 billion alternative to traditional Nuclear VQ imaging in the U.S.

Collaboration with Philips

During the event, 4DMedical partnered with Philips to demonstrate the advanced diagnostic capabilities of CT:VQ. The session, titled “Innovation, Partnerships – for Lung Health and Veterans: Philips and 4DMedical,” focused on improving diagnostic precision and enhancing access to healthcare solutions, particularly for Veterans suffering from deployment-related respiratory diseases.

CT:VQ’s Advantages

CT:VQ offers comparable diagnostic capabilities to Nuclear VQ scans without the use of radioactive materials. It integrates seamlessly into existing hospital infrastructure, making it a scalable solution for broader patient access. The potential for CT:VQ to streamline clinical workflows and reduce patient wait times was well received among healthcare professionals.

Future Outlook

Andreas Fouras, Managing Director and CEO of 4DMedical, commented on the promising progress of CT:VQ, stating, “We are incredibly excited by recent progress we have made with CT:VQ. The Company is well advanced in the completion of its FDA submission which we are targeting for mid-2025.” The recent funding from a successful CRC-P grant will further advance the clinical validation of this technology.

Clinical Need

Nuclear VQ scans are currently utilized for diagnosing various pulmonary conditions. However, CT:VQ’s faster, safer approach with improved accessibility positions it as an essential tool for clinicians navigating the complexities of lung health management.

View Original Accouncement

here

Motley Fool contributor Abbie Stokes has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.